Improvement of pyoderma gangrenosum and psoriasis associated with crohn disease with anti-tumor necrosis factor α monoclonal antibody

Archives of Dermatology

Volumn 137, Issue 7, 2001, Pages 930-933

  Tan, Mei Heng ^a   Gordon, Marsha ^a   Lebwohl, Oscar ^a   George, James ^a   Lebwohl, Mark G ^b  

^a NEW YORK UNIVERSITY   (United States)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; AZATHIOPRINE; CALCIPOTRIOL; CLOBETASOL; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; METRONIDAZOLE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RIFAMPICIN; SALAZOSULFAPYRIDINE; TACROLIMUS; TAZAROTENE; THALIDOMIDE; TRIAMCINOLONE ACETONIDE;

ADULT; ANUS FISTULA; ARTICLE; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; DRUG EFFICACY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PSORIASIS; PYODERMA GANGRENOSUM; RECTUM FISTULA;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; PSORIASIS; PYODERMA GANGRENOSUM; RECTAL FISTULA; SKIN; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034948308     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions
2. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
3. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
4. Infliximab for the treatment of fistulas in patients with Crohn's disease
5. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis
6. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
7. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease
8. Enhanced secretion of tumor necrosis factor α, IL-6, and IL-1-β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease
9. Soluble IL2 and TNF receptor p55 and p75 in Crohn's disease
10. Anti-TNFα therapy decreases production of chemokines in patients with Crohn's disease
11. Pyoderma gangrenosum
12. Abnormal cell proliferation in psoriasis
13. Pyoderma gangrenosum: Clinical and laboratory findings in 15 patients with special reference to polyarthritis
14. Hyperimmunoglobulin E and impaired neutrophil functions in a case of pyoderma gangrenosum: Effect of clofazimine
15. The effects of cyclosporine A on T lymphocyte and dendritic cell sub-populations in psoriasis
16. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
17. CTLA41g-mediated blockade of T cell costimulation in patients with psoriasis vulgaris
18. Infliximab: A novel chimeric monoclonal antibody for the treatment of Crohn's disease
19. Tumor necrosis factor (TNF)
20. Tumor necrosis factor and Crohn's disease
21. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor-α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
22. Immunomodulation of Crohn's disease using TNF-α neutralizing monoclonal antibodies
23. Anti-TNF strategies in Crohn's disease: Mechanisms, clinical effects, indications
24. Antibodies to tumour necrosis factor α as treatment for Crohn's disease